Company Description
BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging.
Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging.
Azelaprag, our lead product candidate, demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function in preclinical obesity models.
These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period.
We plan to assess azelaprag’s potential to drive significant improvements in weight loss when combined with a GLP-1R agonist in two Phase 2 clinical trials.
We believe these trials will directly support our ultimate therapeutic goal of developing an all-oral combination product for obesity.
| Country | United States |
| Founded | 2015 |
| IPO Date | Sep 26, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 60 |
| CEO | Kristen Fortney, Ph.D. |
Contact Details
Address: 1445A South 50th Street Richmond, CA 94804 United States | |
| Phone | (510) 806-1445 |
| Website | bioagelabs.com |
Stock Details
| Ticker Symbol | BIOA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001709941 |
| Employer ID | 47-4721157 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kristen Fortney, Ph.D. | Chief Executive Officer, President and Director |
| Dov Goldstein, M.D. | Chief Financial Officer |
| Eric Morgen, M.D. | Chief Operating Officer and Director |
| Paul Rubin, M.D. | Chief Medical Officer |
| Jean-Pierre Garnier, Ph.D. | Chair of the Board |
| Michael Davidson, M.D. | Director |
| Patrick Enright | Director |
| James Healy, M.D., Ph.D. | Director |
| Rekha Hemrajani | Director |
| Vijay Pande, Ph.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 26, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Sep 26, 2024 | 424B4 | Prospectus |
| Sep 25, 2024 | EFFECT | Notice of Effectiveness |
| Sep 25, 2024 | S-1MEF | Registration adding securities to prior Form S-1 registration |
| Sep 25, 2024 | CERT | Certification by an exchange approving securities for listing |
| Sep 25, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Sep 18, 2024 | 8-A12B | Registration of securities |
| Sep 18, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Sep 3, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Aug 5, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |